The global bronchoscopes market is witnessing substantial growth as healthcare providers increasingly adopt advanced respiratory diagnostic technologies to address the rising burden of lung cancer, chronic obstructive pulmonary disease (COPD), pneumonia, and other respiratory disorders. According to the latest market analysis, the global bronchoscopes market was valued at USD 4.27 billion in 2025 and is projected to grow from USD 4.58 billion in 2026 to USD 8.13 billion by 2034, registering a CAGR of 7.43% during the forecast period (2026–2034).

Bronchoscopes have become indispensable tools in modern pulmonary medicine, enabling physicians to perform minimally invasive airway examinations, tissue biopsies, and therapeutic interventions with greater precision. Technological advancements in imaging systems, artificial intelligence, robotic-assisted navigation, and single-use bronchoscopy devices are transforming respiratory care and driving market expansion worldwide.

Market Dynamics and Core Insights

AI and Robotic Technologies Revolutionizing Bronchoscopy Procedures

Artificial intelligence is significantly enhancing bronchoscopy by improving lesion detection, real-time image analysis, and procedural navigation. AI-powered systems enable clinicians to identify abnormalities with greater accuracy while supporting more precise biopsy targeting and early disease diagnosis.

Industry leaders are integrating AI into advanced bronchoscopy platforms. Olympus has incorporated AI-enhanced imaging capabilities into its EVIS X1 platform, while Medtronic continues to expand AI-assisted navigation and lung mapping technologies that improve diagnostic outcomes for complex pulmonary cases.

Rising Adoption of Single-Use Bronchoscopes

Healthcare facilities worldwide are increasingly shifting toward disposable bronchoscopes to reduce infection risks and eliminate concerns associated with scope reprocessing and cross-contamination. Single-use devices have become particularly valuable in intensive care units (ICUs), emergency departments, and infection-sensitive clinical settings.

Growing concerns regarding multidrug-resistant infections and stricter hospital infection-prevention protocols continue to accelerate demand for disposable bronchoscopy solutions.

Demand for Advanced Lung Cancer Diagnostics Accelerates Growth

The growing prevalence of lung cancer remains one of the strongest market drivers. Increasing adoption of robotic-assisted bronchoscopy and AI-based CT-bronchoscopy fusion technologies allows physicians to accurately access peripheral lung nodules and obtain diagnostic samples with minimal invasiveness.

As healthcare systems prioritize earlier detection and intervention, bronchoscopy procedures are becoming increasingly integrated into lung cancer screening programs worldwide.

Regional Analysis

North America Maintains Market Leadership

North America accounted for 42.14% of global market revenue in 2025, maintaining its position as the largest regional market. The region benefits from advanced healthcare infrastructure, widespread adoption of robotic bronchoscopy systems, strong reimbursement frameworks, and increasing utilization of AI-powered diagnostic platforms.

The United States remains the primary growth engine, supported by leading academic medical centers, high lung cancer screening rates, and ongoing investments in advanced pulmonary diagnostics.

Asia-Pacific Emerges as the Fastest-Growing Market

Asia-Pacific is expected to register the fastest growth, expanding at a CAGR of 9.45% during the forecast period. Rapid healthcare modernization, increasing respiratory disease prevalence, expanding lung cancer screening programs, and growing investments in advanced medical technologies are driving regional growth.

Countries such as China, Singapore, Australia, and India are actively adopting AI-enabled bronchoscopy systems and navigation-assisted diagnostic platforms to improve respiratory care outcomes.

Europe Continues Strong Expansion

European markets continue to benefit from growing demand for minimally invasive respiratory diagnostics, increasing adoption of digital bronchoscopy technologies, and expanding healthcare investments aimed at improving early disease detection and pulmonary care management.

Segment Analysis

By Product

• Flexible Bronchoscopes are projected to grow at a CAGR of 8.07%, driven by superior patient comfort, deeper airway accessibility, and expanding use in minimally invasive diagnostics.

• Rigid Bronchoscopes are expected to grow at a CAGR of 7.69%, supported by demand for therapeutic procedures, foreign body removal, and airway obstruction management.

By Usage

• Disposable Bronchoscopes are expected to expand at a CAGR of 8.14%, reflecting growing preference for infection control and operational efficiency.

• Reusable Bronchoscopes are projected to grow at a CAGR of 7.93%, supported by continued demand for advanced imaging performance in tertiary care settings.

By Application

The Oncology segment dominated the market with a 37.22% share in 2025, fueled by increasing lung cancer incidence and demand for accurate, minimally invasive tumor diagnosis.

The ICU Airway Management segment is projected to grow at a CAGR of 8.56%, driven by increasing cases of respiratory failure, pneumonia, and critical care admissions.

By End User

Hospitals accounted for 72.88% of total market revenue in 2025, supported by advanced infrastructure and specialist expertise.

Ambulatory Surgical Centers (ASCs) are expected to witness rapid growth at a CAGR of 9.04%, reflecting increasing demand for cost-effective outpatient respiratory procedures.

Key Market Players

1. Olympus Corporation (Japan)
   A global leader in endoscopy technologies, Olympus continues to advance bronchoscopy innovation through AI-enabled imaging systems and enhanced diagnostic visualization platforms.

2. Boston Scientific Corporation (US)
   The company focuses on advanced pulmonary navigation technologies and minimally invasive diagnostic solutions designed to improve lung cancer detection outcomes.

3. FUJIFILM Holdings Corporation (Japan)
   FUJIFILM is expanding its respiratory endoscopy portfolio through advanced imaging technologies and high-definition bronchoscopy solutions.

4. KARL STORZ SE & Co. KG (Germany)
   Renowned for precision endoscopic systems, KARL STORZ continues to support pulmonary diagnostics through innovative visualization and instrumentation technologies.

5. Ambu A/S (Denmark)
   Ambu remains a pioneer in single-use bronchoscopy, helping healthcare facilities improve infection prevention and workflow efficiency.

6. HOYA Corporation (Japan)
   Through its healthcare divisions, HOYA supports advanced endoscopy innovation and imaging solutions for respiratory medicine.

7. Teleflex Incorporated (US)
   Teleflex provides airway management and bronchoscopy technologies that support critical care and interventional pulmonology procedures.

8. Medtronic plc (Ireland)
   Medtronic is a leading innovator in AI-assisted navigation bronchoscopy and lung mapping systems for early lung cancer diagnosis.

9. Richard Wolf GmbH (Germany)
   The company offers advanced endoscopic equipment designed to improve diagnostic accuracy and therapeutic intervention capabilities.

10. Cook Medical (US)
    Cook Medical continues to strengthen its pulmonary intervention portfolio through specialized bronchoscopy accessories and procedural tools.

Recent Industry Developments

• October 2025: PENTAX Medical signed an asset purchase agreement with Merit Medical Systems to divest its C2 CryoBalloon therapeutic endoscopy business and sharpen focus on reusable endoscopy technologies.

• September 2025: Olympus Corporation initiated a Class 1 recall involving selected bronchoscopy systems to update safety guidance related to laser and high-frequency therapeutic procedures.

• August 2025: Body Vision Medical received regulatory approval in Singapore for commercialization of its AI-powered LungVision bronchoscopy platform.

• August 2025: Shanghai AnQing Medical Instrument Co., Ltd. secured U.S. FDA 510(k) clearance for its flexible bronchoscope portfolio.

• August 2025: Zhejiang UE Medical Corp. obtained U.S. FDA 510(k) clearance for multiple single-use bronchoscope products and display systems.

Industry Impact and Future Outlook

The future of the bronchoscopes market is expected to be defined by artificial intelligence, robotic navigation, advanced imaging systems, and infection-control innovations. As healthcare providers increasingly prioritize early lung cancer detection, precision respiratory diagnostics, and minimally invasive procedures, bronchoscopy technologies will play an increasingly critical role in pulmonary care.

Growing demand for outpatient respiratory interventions, expanding adoption of AI-assisted clinical decision support systems, and continuous advancements in single-use bronchoscopy are expected to reshape the market over the next decade. Manufacturers investing in digital integration, procedural automation, and enhanced diagnostic accuracy will be well-positioned to capture emerging opportunities in this rapidly evolving healthcare landscape.

Gain access to expanded insights on competitive strategies, market size, and regional analysis. View our Market Report Overview here:https://straitsresearch.com/report/bronchoscopes-market 

About Straits Research

Straits Research is a leading global provider of market intelligence, consulting, and advisory services. The company delivers comprehensive research reports and actionable insights across healthcare, technology, industrial, consumer goods, and emerging sectors worldwide.

With a team of experienced analysts and industry experts, Straits Research helps organizations identify growth opportunities, evaluate competitive landscapes, and develop data-driven business strategies. The firm is committed to providing accurate, reliable, and forward-looking market intelligence that supports informed decision-making and sustainable growth.